HHS: Providers should order antibody therapies directly from distributor

Feb 22, 2021 - 03:02 PM
HHS Logo web sized 900x400

Authorized health care providers should now order the monoclonal antibody therapy bamlanivimab and antibody cocktail casirivimab/imdevimab directly from the sole distributor, AmerisourceBergen Corp., the Department of Health and Human Services announced Friday.

HHS’ Office of the Assistant Secretary for Preparedness and Response will no longer allocate the therapies to health departments because the drugs are no longer in short supply, the agency said, noting that the products remain free of charge to requesting sites. “HHS will continue to monitor all direct orders, and we retain the capacity to resume allocation of these and future therapies if needed.” For more on the direct ordering process, see the ASPR guide.

The Food and Drug Administration in November issued emergency use authorizations for bamlanivimab and casirivimab/imdevimab to treat certain COVID-19 outpatients at risk for severe disease.

Related News Articles

Headline
HHS announces efforts to improve long COVID care 
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
FDA issues serious recall for electric wheelchair joysticks
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
CDC releases 2025-26 respiratory disease season outlook
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
OSHA extends comment period on proposal removing remaining COVID-19 emergency temporary standard requirements
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…
Headline
CDC says COVID-19 cases growing or likely growing in 45 states 
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
FDA announces recall of cefazolin by Sandoz for mislabeling
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…